Enanta Pharmaceuticals, Inc. (ENTA)
11.55
+0.37
(+3.31%)
USD |
NASDAQ |
Oct 15, 09:50
Enanta Pharmaceuticals Total Long Term Debt (Quarterly) : 178.13M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 178.13M |
| March 31, 2026 | 182.86M |
| December 31, 2025 | 189.90M |
| September 30, 2025 | 197.91M |
| June 30, 2025 | 204.70M |
| March 31, 2025 | 213.95M |
| December 31, 2024 | 220.28M |
| September 30, 2024 | 224.53M |
| June 30, 2024 | 223.74M |
| March 31, 2024 | 226.28M |
| December 31, 2023 | 210.07M |
| September 30, 2023 | 217.17M |
| June 30, 2023 | 225.43M |
| March 31, 2023 | 24.50M |
| December 31, 2022 | 23.28M |
| September 30, 2022 | 23.80M |
| June 30, 2022 | 23.72M |
| March 31, 2022 | 16.62M |
| December 31, 2021 | 17.46M |
| September 30, 2021 | 2.632M |
| June 30, 2021 | 3.116M |
| March 31, 2021 | 4.123M |
| December 31, 2020 | 4.999M |
| September 30, 2020 | 5.317M |
| June 30, 2020 | 6.175M |
| Date | Value |
|---|---|
| March 31, 2020 | 6.958M |
| December 31, 2019 | 7.615M |
| September 30, 2019 | 1.828M |
| June 30, 2019 | 1.852M |
| March 31, 2019 | 1.877M |
| December 31, 2018 | 1.899M |
| September 30, 2018 | 1.921M |
| June 30, 2018 | 1.843M |
| March 31, 2018 | 1.865M |
| December 31, 2017 | 1.886M |
| September 30, 2017 | 1.22M |
| June 30, 2017 | 0.641M |
| March 31, 2017 | 0.658M |
| December 31, 2016 | 0.676M |
| September 30, 2016 | 0.69M |
| June 30, 2016 | 0.707M |
| March 31, 2016 | 0.721M |
| December 31, 2015 | 0.746M |
| September 30, 2015 | 0.761M |
| June 30, 2015 | 0.36M |
| March 31, 2015 | 0.185M |
| December 31, 2014 | 0.183M |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | 2.866M |
| Coherus Oncology, Inc. | 52.23M |
| BridgeBio Pharma, Inc. | 3.370B |
| RenovoRx, Inc. | 0.259M |
| ACADIA Pharmaceuticals, Inc. | 59.55M |